The Transcatheter Valve Revolution: Time for a Compensatory Pause
The last 2 years have seen a torrent of information regarding transcatheter aortic valve replacement (TAVR), and it is no exaggeration to say that this compelling technology has revolutionized our approach to treatment of valvular aortic stenosis. High risk and inoperable patients heretofore relegated to minimally effective medical therapies have been offered a return to activity and in some cases, a longer life1,2. (SELECT FULL TEXT TO CONTINUE)
- Received July 2, 2012.
- Accepted July 5, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited